title: Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?
abstract: OBJECTIVE
  To compare the efficiency and ocular side-effect profile of topical loteprednol applied to one eye and topical dexamethasone applied to the other eye in the early period on the same patient who has subepithelial infiltrates (SEI).
  
  
  METHODS
  The patients who developed bilateral SEI following epidemic keratoconjunctivitis (EKC) were applied topical loteprednol on one eye (group 2) and topical dexamethasone on the other (group 1).
  
  
  RESULTS
  Decrease in the symptoms was faster in the dexamethasone group, but this difference between the groups was not statistically significant (p = 0.073). Both groups were found to have substantial recurrence. However, the difference between the groups was not statistically significant (p = 0.131).
  
  
  CONCLUSIONS
  The study has found that in the treatment of SEI, which developed after EKC, statistically similar results can be obtained with loteprednol, which is known to have fewer adverse effects.
authors.affiliation: a Adana Numune Training and Research Hospital , Eye Department , Adana , Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Koçluk
authors.affiliation: a Adana Numune Training and Research Hospital , Eye Department , Adana , Turkey.
authors.forename: Emine Alyamaç
authors.initials: EA
authors.lastname: Sukgen
authors.affiliation: a Adana Numune Training and Research Hospital , Eye Department , Adana , Turkey.
authors.forename: Selim
authors.initials: S
authors.lastname: Cevher
authors.affiliation: b Ersin Arslan State Hospital , Eye Clinic , Gaziantep , Turkey.
authors.forename: Emrah
authors.initials: E
authors.lastname: Mat
mesh_terms: D000258:Adenovirus Infections, Human / Q000188:drug therapy*; D060433:Administration, Ophthalmic; D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003236:Conjunctivitis, Viral / Q000188:drug therapy*; D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology; D003319:Corneal Stroma / Q000187:drug effects / Q000473:pathology; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D019573:Epithelium, Corneal / Q000187:drug effects* / Q000473:pathology; D015828:Eye Infections, Viral / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069559:Loteprednol Etabonate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D003907:Dexamethasone; D000069559:Loteprednol Etabonate
keywords: Epidemic keratoconjunctivitis; subepithelial corneal infiltrates; topical dexamethasone; topical loteprednol